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Re: Secondary Medical Prevention in Patients with Peripheral
Arterial Disease
O. Schouten,1 G.M.J.M. Welten,1 J.J. Bax2 and D. Poldermans3*
1Department of Vascular Surgery, Erasmus MC, Rotterdam, 2Department of Cardiology, Leiden University Medical
Center, Leiden, and 3Department of Anesthesiology, Erasmus MC, Rotterdam, The NetherlandsThe 5-year event rate of patientswith peripheral arterial
disease (PAD) ishigh.TheReductionofAtherothrombo-
sis for Continued Health (REACH) Registry, including
55814 patients with known atherosclerotic disease (cor-
onary artery disease, peripheral arterial disease and ce-
rebrovascular disease) showed that patients with
polyvascular disease have a significant worse outcome
compared to patients with coronary artery disease
only.1 The adverse event rate increasedwith the number
of affected vascular beds from 13% for patients with 1,
21% for patients with 2, and 26% for patients with 3
symptomatic arterial disease locations.
The cause of this high event rate in polyvascular dis-
ease ismultifactorial. In the present study patientswith
PADwere significantly less likely to receive cardiovas-
cular therapy; i.e. antiplatelet therapy, statins, ACE-
inhibitors, and beta-blockers.2 For all therapies there
is substantial evidence that these are associated with
an improved event-free survival. A limitation of the
present study is the lack of follow-up data.
The consultation of PAD patients by the vascular
surgeon offers an unique opportunity to implement
cardiovascular medical therapy according to the cur-
rent guidelines.3 The recent guidelines include clear
recommendations concerning medical treatment of
patients with PAD.
Statins
Treatment target is a LDL cholesterol level of less than
100 mg/dL. Furthermore it is reasonable to aim at
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for patients with PAD at very high risk of ischemic
events.
Antihypertensive Medication
Treatment target is a blood pressure of less than
140 mm Hg systolic over 90 mm Hg diastolic
(non-diabetics) or less than 130 mm Hg systolic over
80 mm Hg diastolic (diabetics and individuals with
chronic renal disease). Thiazides and ACE inhibitors
should be considered as initial blood-pressure lower-
ing drugs. Importantly, beta-adrenergic blocking
drugs are effective antihypertensive agents and are
not contraindicated in patients with PAD.
Antiplatelet Medication
Aspirin, in daily doses of 75e325 mg therapy is indi-
cated to reduce the risk of MI, stroke, or vascular death
in individuals with atherosclerotic PAD. Clopidogrel
(75 mg/day) is effective in reducing cardiovascular
events in a subgroup of patients with symptomatic.
PAD, with or without other clinical evidence of cardio-
vascular disease.
Conclusion
The current study by Gasse et al. clearly reveals the
need for more awareness of routine and continued
medical therapy in patients with PAD. To improve
this awareness, protocols should be developed and
implemented in clinical practice. Future surveys are
important to assess improvement of medical therapy
over time and to explore reasons for not adhering to
recommended treatment strategies.n behalf of European Society for Vascular Surgery.
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